Aida Mujaković
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aida Mujaković has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Edin Begic
Department of Pharmacology, Sarajevo Medical School, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina
5 shared publications - Besim Prnjavorac
Department of Pathophysiology, School of Medicine, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina
4 shared publications - Nejra Mlaco-Vrazalic
School of Medicine, University of Sarajevo
3 shared publications - Ada Đozić
Cardiology Department, General Hospital “Prim. Dr Abdulah Nakaš”, Sarajevo, Bosnia and Herzegovina
2 shared publications - Amer Iglica
Clinical Centre University of Sarajevo
2 shared publications Avdo Kurtović
Primary Healthcare Centre Gracanica
2 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 23 (2)
Analysis of the effects of heat-not-burn tobacco product use on cardiorespiratory symptoms in adults
Aim: To determine if heat-not-burn (HNB) tobacco products are a safe alternative to cigarette smoking by inducing decreased decline of cardiorespiratory function. Methods: A clinical observational, cross-sectional study was conducted in the period between February and June 2025. It analysed and identified the effects of HNB tobacco products on cardiorespiratory symptoms in 60 adults below 55 years of age with confirmed arterial hypertension, 30 in the HNB users group (≥6 months of HNB use and no history of conventional cigarette use (CCU)), and 30 in the non-HNB user group (no history of HNB or CCU). Results: The gender distribution among the groups was similar. HNB tobacco product users reported significantly more respiratory (daily and nighttime shortness of breath, coughing) and cardiologic symptoms (choking, shortness of breath during physical activity). The following parameters were significantly reduced in the HNB tobacco product users: forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and forced expiratory flow at 75% (FEF75) (p = 0.01), SO₂ (p < 0.001), pO₂ (p = 0.001), HCO₃⁻ (p < 0.001), total cholesterol (p = 0.001), and basophils (p < 0.001), while the following parameters were significantly increased in the same group: right ventricular systolic pressure (RVSP) (p = 0.002), hsCRP (p < 0.001), monocytes (p < 0.001), eosinophils (p < 0.001), D-dimer (p < 0.001), and platelet count (p = 0.003). Conclusion: HNB tobacco product use in adults with arterial hypertension was associated with worse cardiorespiratory symptoms, impaired pulmonary function, signs of early right ventricular dysfunction, and systemic inflammation.
- 17 June 2026
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 23 (2)
Open AccessAnalysis of the effects of heat-not-burn tobacco product use on cardiorespiratory symptoms in adults
Aim: To determine if heat-not-burn (HNB) tobacco products are a safe alternative to cigarette smoking by inducing decreased decline of cardiorespiratory function. Methods: A clinical observational, cross-sectional study was conducted in the period between February and June 2025. It analysed and identified the effects of HNB tobacco products on cardiorespiratory symptoms in 60 adults below 55 years of age with confirmed arterial hypertension, 30 in the HNB users group (≥6 months of HNB use and no history of conventional cigarette use (CCU)), and 30 in the non-HNB user group (no history of HNB or CCU). Results: The gender distribution among the groups was similar. HNB tobacco product users reported significantly more respiratory (daily and nighttime shortness of breath, coughing) and cardiologic symptoms (choking, shortness of breath during physical activity). The following parameters were significantly reduced in the HNB tobacco product users: forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and forced expiratory flow at 75% (FEF75) (p = 0.01), SO₂ (p < 0.001), pO₂ (p = 0.001), HCO₃⁻ (p < 0.001), total cholesterol (p = 0.001), and basophils (p < 0.001), while the following parameters were significantly increased in the same group: right ventricular systolic pressure (RVSP) (p = 0.002), hsCRP (p < 0.001), monocytes (p < 0.001), eosinophils (p < 0.001), D-dimer (p < 0.001), and platelet count (p = 0.003). Conclusion: HNB tobacco product use in adults with arterial hypertension was associated with worse cardiorespiratory symptoms, impaired pulmonary function, signs of early right ventricular dysfunction, and systemic inflammation.
- Open Access
- 1 January 2025
- Published by Medical Association of the Sarajevo Canton
- Vol. 2 (2) , 98-109
Comparison of Heat-not-Burn-Tobacco-Products and Cigarette Use Effect on Lung Health Deterioration in Adults – A Single Center Experience
Introduction. The harmful effect of cigarette use has been proven through existing studies, but the recent advanced use of heat-not-burn-tobacco-products (HNB) and its effect remains under observation. Results. After six months, HNB users exhibited better-preserved FEV1 and peripheral oxygenation values. Conclusion. Patients using HNB tobacco products achieved better 6MWT and spirometry testing results and showed lower cholesterol and hs-CRP levels after six months of follow-up. Keywords: smoking, spirometry, heat-not-burn, lung function decline, respiratory health.
- 1 January 2025
- Published by Medical Association of the Sarajevo Canton
- Vol. 2 (2) , 98-109
Open AccessComparison of Heat-not-Burn-Tobacco-Products and Cigarette Use Effect on Lung Health Deterioration in Adults – A Single Center Experience
Introduction. The harmful effect of cigarette use has been proven through existing studies, but the recent advanced use of heat-not-burn-tobacco-products (HNB) and its effect remains under observation. Results. After six months, HNB users exhibited better-preserved FEV1 and peripheral oxygenation values. Conclusion. Patients using HNB tobacco products achieved better 6MWT and spirometry testing results and showed lower cholesterol and hs-CRP levels after six months of follow-up. Keywords: smoking, spirometry, heat-not-burn, lung function decline, respiratory health.
- Open Access
- 27 August 2022
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 20 (1) , 45-51
Parameters in predicting the risk of a prolonged hospital stay in patients with acute exacerbation of chronic obstructive pulmonary disease: a single-centre experience
Aim To identify clinical and laboratory parameters on admission and/or during a hospital stay that would predict prolonged hospital stay in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Methods A retrospective cross-sectional study was conducted at the Clinic for Pulmonary Diseases and Tuberculosis, Clinical Centre University of Sarajevo for the period 2019-2021 accounting patients admitted due to AECOPD. The need for hospitalization was evaluated according to the current GOLD criteria and certain clinical parameters. Spirometry testing and laboratory analysis were performed for all patients on the day of admission and on the 10th day of hospital stay. Linear regression was used to show the relationship between multiple independent predictor variablesand LOS.Results A total of 50 patients were evaluated during their hospital stay due to AECOPD. Median of LOS was 22.02±1.06, with 90%hospital survival rate. Due to AECOPD the median of LOS in the intensive care unit (ICU) was 4±0.68 days with pH<7.35 in 34% of hospitalized patients. According to spirometry classification on the day of admission, 56% of patients were assigned to group 3 and 16% to group 4 with significant improvement identified on spirometry findings on discharge. Platelets on the day of admission were the only statistically significant positive predictors of the length of hospital stay.Conclusion Identifying chronic obstructive pulmonary disease patients at risk of frequent exacerbations and appropriate diseasemanagement could reduce the disease burden.
- 27 August 2022
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 20 (1) , 45-51
Open AccessParameters in predicting the risk of a prolonged hospital stay in patients with acute exacerbation of chronic obstructive pulmonary disease: a single-centre experience
Aim To identify clinical and laboratory parameters on admission and/or during a hospital stay that would predict prolonged hospital stay in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Methods A retrospective cross-sectional study was conducted at the Clinic for Pulmonary Diseases and Tuberculosis, Clinical Centre University of Sarajevo for the period 2019-2021 accounting patients admitted due to AECOPD. The need for hospitalization was evaluated according to the current GOLD criteria and certain clinical parameters. Spirometry testing and laboratory analysis were performed for all patients on the day of admission and on the 10th day of hospital stay. Linear regression was used to show the relationship between multiple independent predictor variablesand LOS.Results A total of 50 patients were evaluated during their hospital stay due to AECOPD. Median of LOS was 22.02±1.06, with 90%hospital survival rate. Due to AECOPD the median of LOS in the intensive care unit (ICU) was 4±0.68 days with pH<7.35 in 34% of hospitalized patients. According to spirometry classification on the day of admission, 56% of patients were assigned to group 3 and 16% to group 4 with significant improvement identified on spirometry findings on discharge. Platelets on the day of admission were the only statistically significant positive predictors of the length of hospital stay.Conclusion Identifying chronic obstructive pulmonary disease patients at risk of frequent exacerbations and appropriate diseasemanagement could reduce the disease burden.
- 2 July 2022
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 19 (2) , 160-165
Can neutrophil-to-lymphocyte ratio and proatherogenic risk factors improve the accuracy of pneumonia severity index in the prediction of community acquired pneumonia outcome in healthy individuals?
Aim To investigate influence of neutrophil-to-lymphocyte ratio (NLR) and proatherogenic risk factors to improve the accuracyof pneumonia severity index (PSI) in the prediction of community acquired pneumonia (CAP) outcome in healthy individuals.Methods A retrospective observational cross-sectional study conducted at the Clinic for Pulmonary Diseases and Tuberculosis “Podhrastovi”, University Clinical Centre Sarajevo, included 83 patients with the diagnosis of CAP during the period March2019-March 2021. Once diagnosed with CAP, PSI score was calculated and according to its value the need for hospital treatment was identified. Patients were divided in two groups: low risk of CAP (PSI 90).Results The overall average hospital stay was 22.76±10.154 days. In the patients diagnosed with CAP, a positive correlation wasestablished between the following parameters PSI score and age (r=0.670; p<0.01), C-reactive protein-CRP (rho=0.287; p<0.01), leukocytes (rho=0.406; p<0.01), NLR (rho=0.313; p<0.01) and platelet to lymphocyte ratio (PLR) (0.296; p<0.05). CRP, leukocytes, NLR and PLR were statistically significantly higher in patients with high risk of CAP compared to patients with low risk of CAP. Diastolic blood pressure, lymphocytes, eosinophils were significantly lower in patients with high risk of CAP (p<0.05;) compared to patients with low risk of CAP (p<0.01). The optimal cut-off value of NLR for CAP patients was 3.089 with an estimated area under curve (AUC) of 0.664.Conclusion Proatherogenic parameters such as age, systolic blood pressure and leukocytes in combination with neutrophil-lymphocyte count ratio could improve accuracy of the pneumonia severity index in community acquired pneumonia outcome.
- 2 July 2022
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 19 (2) , 160-165
Can neutrophil-to-lymphocyte ratio and proatherogenic risk factors improve the accuracy of pneumonia severity index in the prediction of community acquired pneumonia outcome in healthy individuals?
Aim To investigate influence of neutrophil-to-lymphocyte ratio (NLR) and proatherogenic risk factors to improve the accuracyof pneumonia severity index (PSI) in the prediction of community acquired pneumonia (CAP) outcome in healthy individuals.Methods A retrospective observational cross-sectional study conducted at the Clinic for Pulmonary Diseases and Tuberculosis “Podhrastovi”, University Clinical Centre Sarajevo, included 83 patients with the diagnosis of CAP during the period March2019-March 2021. Once diagnosed with CAP, PSI score was calculated and according to its value the need for hospital treatment was identified. Patients were divided in two groups: low risk of CAP (PSI 90).Results The overall average hospital stay was 22.76±10.154 days. In the patients diagnosed with CAP, a positive correlation wasestablished between the following parameters PSI score and age (r=0.670; p<0.01), C-reactive protein-CRP (rho=0.287; p<0.01), leukocytes (rho=0.406; p<0.01), NLR (rho=0.313; p<0.01) and platelet to lymphocyte ratio (PLR) (0.296; p<0.05). CRP, leukocytes, NLR and PLR were statistically significantly higher in patients with high risk of CAP compared to patients with low risk of CAP. Diastolic blood pressure, lymphocytes, eosinophils were significantly lower in patients with high risk of CAP (p<0.05;) compared to patients with low risk of CAP (p<0.01). The optimal cut-off value of NLR for CAP patients was 3.089 with an estimated area under curve (AUC) of 0.664.Conclusion Proatherogenic parameters such as age, systolic blood pressure and leukocytes in combination with neutrophil-lymphocyte count ratio could improve accuracy of the pneumonia severity index in community acquired pneumonia outcome.
- Open Access
- 8 November 2019
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 19 (4) , 315-320
Adjunct corticosteroid treatment in patients with pneumonia: A precision medicine approach
Pneumonia is the leading infectious cause of death worldwide. While inflammation is critically important in host response to microbial invasion, exaggerated inflammation can damage the lungs, contributing to respiratory failure and mortality. Corticosteroids are effective in reducing inflammation and can also cause immune suppression. Presently, clinicians are unable to reliably distinguish between exaggerated and appropriate immune response and thus cannot rapidly identify patients most likely to benefit from adjunctive corticosteroids. In this review, we propose a biomarker-guided, precision medicine approach to corticosteroid treatment, aimed to give these medications at appropriate dose and time and only to patients who have exaggerated inflammation.
- 8 November 2019
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 19 (4) , 315-320
Open AccessAdjunct corticosteroid treatment in patients with pneumonia: A precision medicine approach
Pneumonia is the leading infectious cause of death worldwide. While inflammation is critically important in host response to microbial invasion, exaggerated inflammation can damage the lungs, contributing to respiratory failure and mortality. Corticosteroids are effective in reducing inflammation and can also cause immune suppression. Presently, clinicians are unable to reliably distinguish between exaggerated and appropriate immune response and thus cannot rapidly identify patients most likely to benefit from adjunctive corticosteroids. In this review, we propose a biomarker-guided, precision medicine approach to corticosteroid treatment, aimed to give these medications at appropriate dose and time and only to patients who have exaggerated inflammation.
- 1 March 2019
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 14 (1-2) , 3-11
Development of Software for Choosing Therapeutic Modalities in Atrial Fibrillation
- 1 March 2019
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 14 (1-2) , 3-11
Development of Software for Choosing Therapeutic Modalities in Atrial Fibrillation
- 1 November 2018
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 13 (11-12) , 457
Software for assessment of bleeding risk scores in atrial fibrillation
- 1 November 2018
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 13 (11-12) , 457
Software for assessment of bleeding risk scores in atrial fibrillation